Dr. Brudno on Allogeneic T Cells Expressing an Anti-CD19 CAR in B-Cell Malignancies
Jennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
Jennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation, without causing graft-versus-host disease.
The phase I study examined CAR T cells in patients who previously received an allogeneic stem cell transplant for CD19-positive B-cell malignancies who failed on previous therapies. T cells that were manipulated to receive the CAR therapy were derived from donors of stem cell transplants.
This marks the first time this was deemed safe for these patients, and there was also no reports of graft-versus-host disease. Toxicities were similar compared with patients who underwent autologous transplants.
<<<
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
